Sevuparin - Modus Therapeutics/Mahidol Oxford Tropical Research Unit

Drug Profile

Sevuparin - Modus Therapeutics/Mahidol Oxford Tropical Research Unit

Alternative Names: DF-02; Low anticoagulant heparin - Modus Therapeutics

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dilafor
  • Developer Arabian Gulf University; Mahidol Oxford Tropical Medicine Research Unit; Modus Therapeutics
  • Class Anti-inflammatories; Anticoagulants; Antimalarials; Antithrombotics; Heparins; Low molecular weight heparins; Polysaccharides
  • Mechanism of Action E-selectin inhibitors; Fibronectin receptor antagonists; L-selectin inhibitors; P selectin inhibitors; Thrombospondin antagonists; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Sickle cell anaemia

Most Recent Events

  • 18 Apr 2018 The US FDA grants rare pediatric disease designation to sevuparin for Sickle cell anaemia
  • 20 Dec 2017 Updated pharmacodynamics data from a phase I/II trial in Falciparum malaria released by Modus Therapeutics
  • 22 Feb 2017 Modus Therapeutics plans clinical trials for Sickle cell anaemia (Modus Therapeutics pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top